---
title: "AstraZeneca falls 6% in regular trading after trial misses endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292290925.md"
description: "AZN drops 6% to $176.91 after Phase III trial failure and securities fraud probe outweigh bullish Citi call."
datetime: "2026-07-10T08:21:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292290925.md)
  - [en](https://longbridge.com/en/news/292290925.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292290925.md)
generator: "portal-rs"
---

# AstraZeneca falls 6% in regular trading after trial misses endpoint

阿斯利康 (AZN.US) 常规交易时段累跌**5.7%**，盘前延续跌势现报**176.91**美元。

股价波动主要受 III 期临床试验 CARDIO-TTRansform 未达主要终点影响，合作药物 Wainua 研发受挫。此外，律所 Levi & Korsinsky 已启动证券欺诈调查，指公司此前关于试验成功的陈述可能误导投资者。尽管花旗维持买入评级及 175 英镑目标价，负面消息仍主导市场情绪。

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)](https://longbridge.com/en/news/296444477.md)
- [Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296674916.md)
- [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md)
- [AstraZeneca Gets U.S. Approval for Hypertension Drug](https://longbridge.com/en/news/286724028.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**